RPTX•benzinga•
Repare Therapeutics Out-Licenses Its Discovery Platforms To DCx Biotherapeutics; Will Receive $4M Upfront And 9.99% Common Equity Position In DCx And Is Eligible For Milestone Payments And Royalties
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 1, 2025 by benzinga